Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.38 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 2/20 | 0.37 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 2/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30987185 | 0.87 | OPRD1 (0.38) | THRBLMNAGPR119USP30GRIN2B | |
| SCHEMBL31735206 | 0.82 | GPR119 (0.47) | GPR119USP30CYP46A1GRIN2BGRM5 | |
| SCHEMBL30987149 | 0.78 | NR1H2 (0.43) | THRBRORC | |
| SCHEMBL30987025 | 0.77 | NR1H2 (0.40) | THRB | |
| SCHEMBL30585014 | 0.76 | CYP46A1 (0.54) | GPR119USP30CYP46A1GRM5GRM1 | |
| SCHEMBL1088021 | 0.76 | CYP46A1 (0.54) | GPR119USP30CYP46A1GRM5GRM1 | |
| SCHEMBL30987104 | 0.76 | NR1H2 (0.41) | THRBRORC | |
| SCHEMBL30987073 | 0.74 | NR1H2 (0.40) | THRBRORC | |
| SCHEMBL24536252 | 0.73 | NR1H2 (0.45) | THRBRORC | |
| SCHEMBL30987137 | 0.73 | NR1H2 (0.45) | THRBRORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479837-B2 | Reversible DPP1 inhibitors and uses thereof | INSMED INCORPORATED (US) | 2025-11-25 | — | — | US | disclosed |
| EP-4646265-A1 | NOVEL, REVERSIBLE DPP1 INHIBITORS AND USES THEREOF | Insmed Incorporated (US) | 2025-11-12 | — | — | EP | disclosed |
| US-20250223284-A1 | REVERSIBLE DPP1 INHIBITORS AND USES THEREOF | INSMED INCORPORATED | 2025-07-10 | — | — | US | disclosed |
| WO-2024148308-A1 | NOVEL, REVERSIBLE DPP1 INHIBITORS AND USES THEREOF | INSMED INCORPORATED (US) | 2024-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250223284-A1 | REVERSIBLE DPP1 INHIBITORS AND USES THEREOF | DPP4, DPP7, DPP9 | THRB 1510/4885LMNA 4053/4885GPR119 24/4885 |
| US-12479837-B2 | Reversible DPP1 inhibitors and uses thereof | DPP4, DPP7, DPP9 | THRB 1510/4885LMNA 4053/4885GPR119 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.